Appendix. Common Proprietary Equivalents of Drugs Mentioned in the Text

Total Page:16

File Type:pdf, Size:1020Kb

Appendix. Common Proprietary Equivalents of Drugs Mentioned in the Text Appendix. Common Proprietary Equivalents of Drugs Mentioned in the Text In the majority of instances, the official names of drugs have been employed throughout the text. However, in practice the urologist will frequently come across drugs under their proprietary names, and their true nature may not be immediately apparent. In order to facilitate identification of the corresponding official names, the most commonly encountered proprietary names of the drugs mentioned in this book, together with their official equivalents, are listed. Proprietary name Official name Adalat Nifedipine Aldomet Methyldopa Aldoril Methyldopa Allegron Nortriptyline HCl Allertab Chlorpheniramine maleate Anectine Suxamethonium Cl, Succinylcholine Cl Ansolysin Pentolinium tartrate Anthisan Mepyramine maleate Apodorm Nitrazepam Apresoline Hydrallazine Arfonad Trimetaphan camsylate Aventyl Nortriptyline HCl Banthine Methantheline Br Benadryl Diphenhydramine HCl Bentyl Dicyclomine HCl Bicor Terodiline HCl Bretylate Bretylium tosylate Brevital Methohexitone Bricanyl Terbutaline sulphate Brietal Methohexitone Brufen Ibuprofen Buscopan Hyoscine butylbromide Catapres Clonidine HCl Catapresan Clonidine HCl Cetiprin Emepronium Br Compazine Prochlorperazine Cordilox Verapamil HCl Cystospaz Hyoscyamine 160 Appendix Proprietary name Official name Danatrol Danazol Danol Danazol Dantrium Dantrolene Na Darbid Isopropamide iodide Darenthin Bretylium tosylate DDAVP Desmopressin Decadron Dexamethasone Decicain Amethocaine HCI Deltacortril Prednisolone Demerol Pethidine, meperidine Deralin Propranolol HCI Dibenyline Phenoxybenzamine HCI Dibenzyline Phenoxybenzamine HCI Dilantin Phenytoin Na, diphenylhydantoin Na Disipal Orphenadrine HCI Ditropan Oxybutynin HCI Dixarit Clonidine HCl DMSO Dimethyl sulphoxide Dolantin Pethidine, meperidine Dolestin Pethidine, meperidine Doryl Carbachol Duvadilan Isoxsuprine HCI Dyspas Dicyclomine HCI Epanutin Phenytoin Na, diphenylhydantoin Na Eskornade Contains: phenylpropanolamine HCI, isopropamide iodide and diphenylpyraline HCI Esracaine Lignocaine Flaxedil Gallamine triethiodide Fluothane Halothane Froben Flurbiprofen Halodol Haloperidol Histadyl Methapyrilene HCI Hypovase Prazosin HCI Inderal Propranolol HCI Indocid Indomethacin Intraval Na Thiopentone Na Intropin Dopamine HCI Inversine Mecamylamine HCI Ismelin Guanethidine monosulphate Isophrin Phenylephrine HCI Isoptin Verapamil Isuprel Isoprenaline HCI, isoproterenol HCI lanimine Imipramine HCI Largactil Chlorpromazine HCI Ledercort Triamcinolone Librium Chlordiazepoxide HCI Lidocaine Lignocaine Appendix 161 Proprietary name Official name Lioresal Baclofen Lopress Hydrallazine Marcain Bupivacaine HO Mecholyl Methacholine CI Mechothane Bethanechol CI Mellaril, Melleril Thioridazine HCI Minipress Prazosin HCI Mistura C Carbachol Mistura D Phenylephrine HCI Mogadon Nitrazepam Myotonine CI Bethanechol CI Neophryn Phenylephrine HCI Neosynephrine Phenylephrine HCI Nipride Sodium nitroprussid~ Norisodrine Isoprenaline HCI, isoproterenol HCI Novalgin Dipyrone Omnopon Papaveretum Optalgin Dipyrone Omade Contains phenylpropanolamine, chlorpheniramine and isopropamide Pamine Methscopolamine Br, hyoscine methobromide Pantocaine Amethocaine HCI Pantopon Papaveretum Paragone Diethylaminoethyl benzilate methobromide Parlodel Bromocriptine mesylate Pavulon Pancuronium Br Pentothal Thiopentone Na Pirtiton Chlorpheniramine maleate Pitocin Oxytocin Pontocaine Amethocaine HCI Pramine Metoclopramide HCI Premarin Mixed conjugated oestrogens Primperan Metoclopramide HCI Pro-Banthine Propantheline Br Propadrine Phenylpropanolamine HO Prostigmin Neostigmine Br Pyribenzamine Tripelennamine citrate Regitine Phentolamine HCI Robinul Glycopyrrolate, glycopyrronium Br Rogitine Phentolamine HCI Scoline Suxamethonium CI, succinylcholine CI Serax Oxazepam Serenace Haloperidol Serenid Oxazepam Sermion Nicergoline Serpasil Reserpine 162 Appendix Proprietary name Official name SK-Pramine Imipramine HCl Stemetil Prochlorperazine Sudafed Pseudoephedrine HCl Tetracaine Amethocaine HCl Thorazine Chlorpromazine HCl Tofranil Imipramine HCl Triominic Contains: phenylpropanolamine HCl, mepyramine maleate and pheniramine maleate Tyrimide Isopropamide iodide Ubretid Distigmine Br Urecholine Bethanechol Cl Urispas Flavoxate HCl Valium Diazepam Valpin Anisotropine methylbromide, octatropine methylbromide Vasoxine Methoxamine HCl Vasoxyl Methoxamine HCl Vegolysin Hexamethonium Ventolin Salbutamol sulphate Voltaren Diclofenac Na Xylocaine Lignocaine Xylotox Lignocaine Subject Index acetylcholine, 104 baclofen, 52. 111 inactivation of, 10 dosage, 93, 112 as neurotransmitter, 6 in neuropathic dysfunction, 52, 93 synthesis of, 9 side-effects, 52, 94, 112 on ureter, 71 on striated muscle, 112 acute retention belladonna, 17 alpha-adrenergic blockade for, 145, 147-148 dosage, 88 causes of, 144 in neuropathic bladder, 88 phentolamine for, 149 side-effects, 88 urodynamic findings in, 144 benzodiazepines, 52-53 adenosine triphosphate (ATP) beta-adrenergic agonists relationship to purinergic nerves, 26 on bladder, 117 role in muscle contraction, 3-4 on striated muscle, 112 adrenaline bethanechol, 16. 104--106 diphasic action, 18 on bladder, 90-91, 104--105; lack of synthesis, 8 response, 105 on ureter, 70 dosage, 91, 105-106 adrenocortical steroids on nicotine receptors, 21 in interstitial cystitis, 154--155 in post-operative retention, 104 mode of action, 153 side-effects, 91 in osteitis pubis, 156 on ureter, 72 in Peyronie's disease, 155-156 bethanechol supersensitivity test, 80-83 in retroperitoneal fibrosis, 154 bladder, autonomic receptors in, 14 side-effects, 153 bretylium, 24 in tuberculous ureteritis, 157 bromocriptine, 20, 110 in urethral stricture, 156 bupivacaine, epidural, effect on urethra, 43 alpha-adrenergic agonists, side-effects, 120 butorphanol, 67 alpha-adrenergic blockers in ureteric colic, 67 inhibiting ganglionic transmission, 107 butoxamine, 20 in ureteric colic. 67 alpha-adrenergic supersensitivity test, 87 calcium, role in muscle contraction, 3-4 amethocaine, in autonomic dysrefiexia, 43 calcium antagonists angiotensin, mode of action, 31 mode of action, 39 anisotropine methylbromide, on bladder, 115 side-effects, 119 anticholinergic therapy calmodulin, 3-4 on bladder, 113-115 carbachol, 16 contraindications, 114 on bladder, 106 side-effects, 114 on nicotinic receptors, 21 atenolol, 20 chlordiazepoxide, see benzodiazepines atropine, 17 chlorpromazine, see phenothiazines blocking effect on histamine, 38 alpha blocking effect, 110 dosage, 114 cholinergic stimulation autonomic dysrefiexia (hyperrefiexia) contraindications, 106 mechanism, 22 side-effects, 106 symptoms, 97 on urethra, 106 treatment, 97 clinical trials, criteria for, 103 autonomic ganglia, receptors in, 21 clonidine, 18, 110 autonomic nervous system cocaine, on uptake I, 9 drug actions on, 15 corticosteroids, see adrenocortical steroids supply to urinary tract, 5-6 cytotoxic drugs, in ureteric neoplasms, 69 164 Subject Index danazol,69 dosage, 116 in ureteric endometriosis, 69 mode of action, 32 dantrolene, 51-52, 111 side-effects, 116 dosage, 94, 111 fiunarizine, on bladder, 118 in neuropathic dysfunction, 51, 94 fiurbiprofen side-effects, 52, 94, 111 in detrusor instability, 37, 117 in striated sphincter dyssynergia, 111 side-effects, 118 toxicity, 51 desmopressin gallamine, see neuromuscular blockers contraindications, 127 gamma-aminobutyric acid (GABA), 52 in diabetes insipidus, 126 glucagon dosage, 126-127 mode of action, 73 in nocturnal enuresis, 127 on ureter, 73-74 in nocturnal frequency, 127 in ureteric colic, 67 diazepam, see also benzodiazepines glycopyrrolate dosage, 93, 110 on bladder, 115 in neuropathic dysfunction, 93-95 dosage, 115 side-effects, 93 guanethidine, 24 for striated muscle relaxation, 111 in autonomic dysrefiexia, 97 diclofenac sodium, in renal colic, 37 for bladder emptying, 107 dicyclomine, 33 dosage, 89, 116 haloperidol, alpha blocking effect, 110 side-effects, 116 hexamethonium, 21 diethylaminoethyl benzilate methobromide, 17 histamine digitalis, on bladder, 41 atropine, partial blockade by, 38 dimethyl sulphoxide, 119 blockers, 38 in interstitial cystitis, 119 mode of action, 73 diphenhydramine, 38 receptors, 37-38 on ureter, 73 on ureter, 73 diphenylhydantoin sodium, on urethra, 20 hydrallazine, on bladder, 33 dipyrone, in renal colic, 65 5-hydroxytryptamine, 38 distigmine, 25 on ureter, 73 on bladder. 106 hyoscine butylbromide, 17 dosage, 106 hyoscyamine, on bladder, 115 dobutamine, 18 hyperrefiexia, of detrusor, 112 dopamine, 18 imipramine emepronium bromide, 17 dosage, 123-124 on bladder. 115 for enuresis, 124 dosage, 115 on lower urinary tract, 122-125 nicotinic blocking effect, 21 modes of action, 25-26 side-effects, 115 musculotropic relaxant effect, 34 ephedrine, 24, 120 side-effects, 124-125 dosage, 90, 120 on uptake I, 9 in incontinence, 24, 121 incontinence, 113 in neuropathic dysfunction, 90 indomethacin causing retention, 24 in detrusor instability, 37. 118 side-effects, 24, 90 in ureteric colic, 37, 72 tachyphylaxis, 120 interstitial cystitis, corticosteroids in. 154-155 on ureter, 70 isoprenaline, 18 on urethra, 24 on ureter. 71 exocytosis, 7, 9 isopropamide. on bladder. 115 isoproterenol. see isoprenaline failure to empty isoxsuprine. 20 causes, 103-104 treatment, 104-112 Jevodopa, 23 failure to store lignocaine, 43 causes, 112-113 in detrusor instability, 43 treatment, 113-126 on ureter. 43-44. 67-68 fiavoxate, 33 on bladder. 116 mecamylamine, 21 Subject Index 165 meperidine, see pethidine nitrazepam,
Recommended publications
  • United States Patent Office
    3,092,548 United States Patent Office Patented June 4, 1963 2 are the various side effects that occur in an appreciable 3,092,548 number of patients, the foremost of which are a blurring METHOD OF TREATING PEPTICULCERS WITH PANTOTHENECACD of vision, drowsiness and a general dry condition mani Albert G. Worton, Columbus, Ohio, assignor to The fested by a retarded salivation, reduction of perspiration Warren-Teed Products Company, Columbus, Ohio, a 5 and diminished urinary output. Other side effects which corporation of Ohio occur in some cases are glaucoma, stimulation of the cen No Drawing. Filed Oct. 27, 1960, Ser. No. 65,256 trol nervous system and in severe cases cardiac and respi 5 Claims. (Ci. 67-55) ratory collapse. These side effects increase to Some de gree with the increase in dosage. Despite the side effects This invention relates to preparation adapted for use O these compounds are fairly selective and highly effective in treating disorders of the gastro-intestinal tract, more in decreasing the volume and acidity of gastric secretion particularly in treating peptic ulcer, both of the duodenal and in reducing gastrointestinal motility. and gastric type, for hyperacidity, hypertropic gastritis, Understandably, the main problem in the past has been splenic flexure syndrome, biliary dyskinesia (postchole to provide a dosage of anticholinergic drug which will cystectomy syndrome) and hiatal hernia or other condi achieve the most beneficial results possible and yet mini tions where anticholinergic effect, either spasmolytic or mize the undesired side effects. One of the objects of antisecretory is indicated or where antiuicerogenic effect this invention is to provide novel compositions containing is indicated.
    [Show full text]
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Norfolk & Waveney Prescriber
    The Norfolk & Waveney Prescriber Issue 119 April 2017 For Primary and Secondary Care Health Professionals in Norfolk & Waveney In this issue: Prescribing Safety News: MHRA Drug Safety Updates 2 TAG and Commissioning News 3-4 Drugs – discontinued, shortages and prices 5-6 Drugs – supply issues 7-8 Guidance and Policy News: - National: “NICE Bites” & NICE guidance 9-10 Guidance and Policy News: - Local: Key Message Bulletins 11-12 Cost-effective Prescribing Tips: 13 Ophthalmic Special Order products Atorvastatin Hot Topic: Multimorbidity and Polypharmacy 14 Prescribing Safety: Medicines and Serotonin Syndrome 15-16 Prescribing Advice: Metformin, Finasteride, and Inhalers 17-18 New Medicines & Indications News 19 Feedback and comments on this edition to [email protected] / 01603 257035 Prescribing & Medicines Management Team – 1 NEL CSU Anglia Prescribing Safety News Main points from MHRA Drug Safety Updates February - March 2017 Articles relevant to Primary Care and Secondary Care: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes. Advice for healthcare professionals: o carefully monitor patients receiving canagliflozin who have risk factors for amputation, such as poor control of diabetes and problems with
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Drug Induced QT Prolongation and Torsades De Pointes (Tdp)
    Drug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013 Conflict of Interest None TdP: Learning objectives To review the pathophysiology of QT prolongation and TdP To become aware of the risk factors (including medication- related) for QT prolongation and TdP To understand and apply a systematic approach for dealing with drug interactions that may cause prolonged QT and TdP Clinical Scenario You receive an order for a patient: Levofloxacin 500 mg PO daily Fluconazole 400 mg PO daily Your drug interaction program flags this as a major interaction due to QT prolonging effect of both drugs increasing risk for TdP. What do you do? TdP: History Quinidine associated syncope since 1920’s Congenital syndromes with prolonged QT and syncope or sudden death described in 1950’s, and early 1960’s. 1966 Francois Dessertenne described a specific EKG form of polymorphic VT he termed “torsades de pointes” Over past decade single most common cause of drug withdrawal/restriction from market 9 structurally unrelated non-cardiac drugs: terfenadine, astemizole, grepafloxicin, terodiline, droperidol, terodiline, droperidol, lidoflazaine, sertindole, levomethadyl, cisapride TdP: Definition Polymorphic VT with a preexistant prolonged QT interval Ventricular Action Potential Ca++ Na+ IKr IKs IKr Channel: hERG controlled Delayed repolarization=prolonged QT interval Mechanism of Torsades de Pointes Early afterdepolarizations (extra beat) Transmural reentry (Unusual pathway) Mechanisms Of Drug - Induced QT Prolongation
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Concentration Dependent Cardiotoxicity of Terodiline in Patients Treated for Urinary Incontinence
    Br HeartJ7 1995;74:53-56 53 Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence Simon H L Thomas, P Daniel Higham, Kenneth Hartigan-Go, Farhad Kamali, Peter Wood, Ronald W F Campbell, Gary A Ford Abstract Terodiline hydrochloride is an antimuscarinic Objective-Terodiline, an antimuscarinic drug with calcium antagonist properties' and calcium antagonist drug, was used to which was used for treating urinary inconti- treat detrusor instability but was with- nence caused by detrusor instability.2 The drawn in 1991 after provoking serious drug was withdrawn in 1991 after reports of ventricular arrhythmias associated with cardiac dysrhythmia including bradycardia, increases in the corrected QT interval heart block, ventricular fibrillation, and ven- (QTc). This research was performed to tricular tachycardia, usually of the torsade de relate drug induced electrocardiographic pointes-type34 and associated with QT pro- changes in asymptomatic recipients to longation. Plasma terodiline concentrations plasma concentrations of the R( +) and were very high in one affected patient. S(-) terodiline enantiomers. Predisposing factors for terodiline associated Setting-Urological and geriatric clinics torsade de pointes were old age, coexisting and wards. ischaemic heart disease, co-prescription of Subjects-Asymptomatic patients taking other cardioactive drugs, and hypokalaemia. terodiline in stable dose. Torsade de pointes is associated with Methods-Electrocardiograms (50 mm/s) abnormal prolongation of the ventricular were collected from patients while they refractory period which results in a long QT were taking terodiline and compared with interval on the electrocardiogram and is often ECGs obtained before or after terodiline. drug induced.5 Increased dispersion of ven- QT interval, heart rate corrected QT tricular recovery may be important in the interval (QTc), and QT dispersion (QTd) development of this arrhythmia and indirect were measured.
    [Show full text]
  • Updatirg the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
    Updatirg the BeersCriteria for Potentially InappropriateMedication Use in Older Adults Resultsof a US ConsensusPanel of Experts DonnaM.Fich,PhD,RN;lamesW.Cooper,PhD,RPh;WilliamE.Wade,PhannD,FASHP,FCCP; JenniJerL. Waller, PhD;J, RossMaclean, MD; Marh H. Beers,MD Bcckground: Medication toxic effectsand drug- Reruhr: This study identified 48 individual medica- relatedproblems can have profound medical and safety tions or classeso[ medicationsto avoid in older adults consequencesfor older adults and economically affect the and their potential concernsand 20 diseases/conditions health caresystem. The purpose of this initiative was to and medicationsto be avoidedin older adultswith these reviseand update the Beerscriteria for potentially inap- conditions.Of thesepotentially inappropriate drugs, 66 propriate medicationuse in adults 65 yearsand older in wereconsidered by the panelto haveadverse outcomes the United States. of high severity. lYlcthcdr: This study used a modified Delphi method, a Concludonr: This study is an importantupdate of pre- setof proceduresand methodsfor formulating a groupjudg- viously establishedcriteria that have been widely used ment for a subject matter in which precise information is and cited. The application of the Beerscriteria and other Iacking. The criteria reviewed covered 2 types of state- tools for identifying potentially inapproprlate medica- ments: (l) medicationsor medicationclasses that should tion use will continue to enableproviders to plan inter- grnerally be avoidedin persons 65 years or older because
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]